This week, five Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).
Insmed Inc.’s (NASDAQ:INSM) grade is moving up to a B (“buy”) this week from last week’s C (“hold”). Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. For more information, get Portfolio Grader’s complete analysis of INSM stock.
Ariad Pharmaceuticals (NASDAQ:ARIA) is seeing ratings go up from a C last week to a B this week. ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. For more information, get Portfolio Grader’s complete analysis of ARIA stock.
The rating of Neurocrine Biosciences (NASDAQ:NBIX) moves up this week, rising from a C to a B. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. The stock price has risen 15.7% over the past month, better than the 0.8% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of NBIX stock.
Array BioPharma (NASDAQ:ARRY) improves from a C to a B rating this week. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. For more information, get Portfolio Grader’s complete analysis of ARRY stock.
Celldex Therapeutics (NASDAQ:CLDX) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. Investors have pushed the stock price up 26.1% over the past month. For more information, get Portfolio Grader’s complete analysis of CLDX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.